REG - Cizzle Biotechnology - Total Voting Rights

Cizzle Biotechnology HoldingsAnnouncement

16/02/2022 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220216:nRSP9094Ba&default-theme=true

RNS Number : 9094B  Cizzle Biotechnology Holdings PLC  16 February 2022

 

16 February 2022

 

Cizzle Biotechnology Holdings Plc

 

("Cizzle Biotechnology", "Cizzle" or the "Company")

 

Total Voting Rights

 

Cizzle Biotechnology, the UK based diagnostics developer, announces a
correction to the total voting rights section of the Company's announcement
made on 14 February 2022 where the nominal value of the Cizzle Biotechnology
ordinary shares was incorrectly stated.  The correct wording is set out
below.

 

Following admission of the 25,000,000 Initial Consideration new Ordinary
Shares to trading on the Standard Segment of the Official List and the Main
Market of the London Stock Exchange ("Admission"), which is expected to become
effective on 17 February 2022, the Company's issued ordinary share capital
will consist of 278,447,788 ordinary shares of 0.01 pence each, all with
voting rights. The Company holds no ordinary shares in Treasury. This figure
may be used by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

All terms in this announcement not defined herein carry the same meaning as in
the Company's announcement made on 14 February 2022.

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe          cizzle@investor-focus.co.uk
 Florence Chandler

 

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer.  Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREASAKFAAAEFA